Estimated VO2Max Validation

Estimated VO2Max Validation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05678530

Recruitment Status : **RECRUITING NOW**
First Posted : January 10, 2023
Last Update Posted : January 10, 2023

Sponsor:

Information provided by (Responsible Party):
physIQ, Inc.

Go to 

Brief Summary:
In this study, the hypothesis being explored is that VO2Max and other CPET parameters can be accurately estimated from biosignals (namely, motion from accelerometers and cardiopulmonary variables from EKG) collected during activities of daily living using wearable biosensors worn by study participants. This study will aim to collect development and validation data for a machine learning algorithm and to evaluate the performance of the algorithm. A total of 300 participants will be enrolled including: (Normal) 200 participants, self-reported healthy male and female participants aged 18 to 80 and (Standard of Care) 100 participants

Heart Failure Healthy

Go to 

Layout table for study information

Study Type :
Observational

Estimated Enrollment :
400 participants

Observational Model:
Case-Control

Time Perspective:
Prospective

Official Title:
Validation of VO2Max Estimations Using Healthy and Standard of Care Participants

Actual Study Start Date :
June 6, 2019

Estimated Primary Completion Date :
June 2023

Estimated Study Completion Date :
August 2023

Go to 

Healthy

Standard of Care

Go to 

Primary Outcome Measures :

Collect development and validation data for a VO2Max (eVO2Max) machine learning algorithm and to evaluate the performance of the algorithm. [ Time Frame: August, 2023 ]
Develop an Estimated VO2Max (eVO2Max) algorithm which will estimate a participant’s VO2Max value using data collected from physiological wearable biosensors (ECG & Activity). This estimation algorithm will be developed using a portion of the collected data (physiological biosignals + CPET) from healthy participants and a portion of data from a separate cohort with a clinical indication requiring functional capacity evaluation (called the Standard of Care Cohort).

Go to 

Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:  
18 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:  
All

Accepts Healthy Volunteers:  
Yes

Sampling Method:  
Probability Sample

Healthy Group: One cohort of participants will be “normal” (healthy) participants who volunteer for CPET testing.
Standard of Care Group: The second cohort of patients will be those with any medical diagnosis that necessitates investigation of functional capacity through cardiopulmonary exercise testing (testing as part of standard of care).

Inclusion Criteria:

Has a clinical indication for investigation of functional capacity through cardiopulmonary exercise testing
Willing and able to comply with protocol procedures
Willing to sign and date informed consent document for study participation

Exclusion Criteria:

Participant has cognitive or physical limitations that, in the opinion of the investigator, limits the participant’s ability to fully follow study procedures and/or reach and respiratory exchange ratio of 1.0
Participant has an allergy to the adhesive used on the VitalPatch
Participant is pregnant, lactating or 30 days post-partum

Go to 

Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05678530

Layout table for location information

physIQ

Chicago, Illinois, United States, 60606

University of Illinois Hospital & Health Sciences System

Chicago, Illinois, United States, 60608

Contact: Dr. Cemal Ozemek    312-355-3996    ozemek@uic.edu   

Principal Investigator: Cemal Ozemek, PhD         

Advocate Aurora Health Institute

Oakbrook Terrace, Illinois, United States, 60181

physIQ, Inc.

Layout table for investigator information

Principal Investigator:
Steve Steinhubl, MD
physIQ, Inc.

Go to 

Layout table for additonal information

Responsible Party:
physIQ, Inc.

ClinicalTrials.gov Identifier:
NCT05678530    

Other Study ID Numbers:
CTP-020

First Posted:
January 10, 2023    Key Record Dates

Last Update Posted:
January 10, 2023

Last Verified:
January 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:
No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:
No

Studies a U.S. FDA-regulated Device Product:
No

Additional relevant MeSH terms:

Layout table for MeSH terms

Heart FailureHeart DiseasesCardiovascular Diseases

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 11, 2023Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments